+124.5%
COST vs GSK
+44.4%
+80.1%
-31.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.3% | +0.5% | +0.8% | +1.2% |
| 7D | +5.0% | +1.1% | +3.9% | +4.8% |
| 30D | +12.8% | +6.3% | +6.5% | +11.6% |
| 3M | +15.2% | +1.8% | +13.4% | +14.7% |
| 6M | +7.4% | +1.7% | +5.8% | +6.9% |
| YTD | +29.0% | +6.5% | +22.5% | +27.2% |
| 1Y | +20.3% | +9.5% | +10.8% | +18.1% |
| 3Y | +99.0% | +65.3% | +33.7% | +79.7% |
| All | +124.5% | +44.4% | +80.1% | +102.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling